- Home
- BOLD vs GDTC Comparison
BOLD vs GDTC Comparison
Compare BOLD & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- GDTC
- Stock Information
- Founded
- BOLD 2018
- GDTC 2018
- Country
- BOLD United States
- GDTC Singapore
- Employees
- BOLD N/A
- GDTC N/A
- Industry
- BOLD
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- GDTC Health Care
- Exchange
- BOLD Nasdaq
- GDTC Nasdaq
- Market Cap
- BOLD 30.3M
- GDTC 28.0M
- IPO Year
- BOLD 2024
- GDTC 2023
- Fundamental
- Price
- BOLD $1.17
- GDTC $2.21
- Analyst Decision
- BOLD Buy
- GDTC Buy
- Analyst Count
- BOLD 3
- GDTC 1
- Target Price
- BOLD $4.00
- GDTC $5.00
- AVG Volume (30 Days)
- BOLD 283.9K
- GDTC 6.5K
- Earning Date
- BOLD 08-11-2025
- GDTC 01-01-0001
- Dividend Yield
- BOLD N/A
- GDTC N/A
- EPS Growth
- BOLD N/A
- GDTC N/A
- EPS
- BOLD N/A
- GDTC N/A
- Revenue
- BOLD N/A
- GDTC $368,838.00
- Revenue This Year
- BOLD N/A
- GDTC $5.37
- Revenue Next Year
- BOLD N/A
- GDTC N/A
- P/E Ratio
- BOLD N/A
- GDTC N/A
- Revenue Growth
- BOLD N/A
- GDTC N/A
- 52 Week Low
- BOLD $1.00
- GDTC $1.20
- 52 Week High
- BOLD $4.72
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- GDTC 49.36
- Support Level
- BOLD N/A
- GDTC $2.09
- Resistance Level
- BOLD N/A
- GDTC $2.35
- Average True Range (ATR)
- BOLD 0.00
- GDTC 0.10
- MACD
- BOLD 0.00
- GDTC 0.00
- Stochastic Oscillator
- BOLD 0.00
- GDTC 50.00
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.